EC145

12/01/2009 - "In conclusion, EC145 is rapidly distributed and eliminated in cancer patients. "
10/01/2007 - "Additional preclinical studies are therefore warranted to better understand EC145's breadth of activity against FR-positive tumors."
05/01/2007 - "Taken together, these studies show that EC145 has significant antiproliferative activity and tolerability, thus lending support to an ongoing phase 1 trial for the treatment of advanced malignancies."
04/15/2014 - "The vintafolide combinations were also studied in mice bearing various FR-expressing tumors. "
03/19/2014 - "The cytotoxic and anti-tumor activity was directly compared to that produced by vintafolide. "

07/01/2015 - "Early-stage clinical data in lung and ovarian cancer suggest that vintafolide has the potential for combination with other standard approved agents. "
04/01/2014 - "In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment. "
04/01/2014 - "Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)."
01/01/2014 - "Vintafolide is a promising targeted agent for recurrent platinum-resistant ovarian cancer, first, thanks to its mechanism of action and the characteristics of FRα in ovarian cancer, and, second, because of the favorable results observed in the first clinical trials on platinum-resistant ovarian cancer. "
03/01/2014 - "A Phase III study evaluating vintafolide plus PLD versus PLD alone in patients with platinum-resistant ovarian cancer is currently underway. "

01/01/2016 - "As the first FR-targeting drug to reach the clinic, vintafolide has achieved favorable responses in phase II clinical trials in FR-positive ovarian and lung cancer. "
10/01/2014 - "The combination of vintafolide plus etarfolatide has been evaluated in three Phase 2 studies for the treatment of various solid tumors, including ovarian, endometrial, peritoneal, and platinum-resistant ovarian cancer, as well as lung cancer. "

03/01/2014 - "Vintafolide: a novel targeted agent for epithelial ovarian cancer."
11/10/2012 - "On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer."
12/10/2013 - "Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. "
03/01/2014 - "Vintafolide (EC145) is a novel folate-conjugated vinca alkaloid (desacetylvinblastine hydrazide; DAVBLH) that binds with high affinity to the folate receptor (FR), expressed in a majority of epithelial ovarian cancers. "

12/01/2009 - "EC145-induced constipation occurs at a higher frequency in the patients with lower EC145 clearance, where the drug exposure tends to be higher."
02/01/2011 - "During a phase I trial of EC145 (a folate-targeted vinca alkaloid conjugate), constipation was identified as the dose-limiting toxicity, probably from a nonfolate receptor-related liver clearance process capable of releasing unconjugated vinca alkaloid from EC145 and shuttling it to the bile. "